<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Local anesthetic systemic toxicity
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Local anesthetic systemic toxicity
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Local anesthetic systemic toxicity
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lisa Warren, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Aimee Pak, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert Maniker, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marianna Crowley, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 25, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2882965310">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Local anesthetics (LAs) are administered in practice by many clinicians, including anesthesiologists, surgeons, emergency department providers, dentists, and others. Despite the widespread use of LAs, awareness of local anesthetic systemic toxicity (LAST) and knowledge of its management are lacking [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         Local anesthetics are often incorrectly thought to be without side effects or toxicity. LAST is always a potential complication, and may occur with all LAs, and any route of administration. LAST primarily affects the central nervous system and cardiovascular system, and may be fatal.
        </p>
        <p>
         This topic will discuss the pathologic pharmacology, mechanisms, and clinical presentation of toxicity, predisposing factors, and prevention and management of LAST. Lipid rescue therapy will also be discussed.
        </p>
        <p class="headingAnchor" id="H3713903370">
         <span class="h1">
          INCIDENCE OF LAST
         </span>
         <span class="headingEndMark">
          —
         </span>
         The reported incidence of major LAST events (ie, seizures or cardiac arrest) associated with regional anesthesia is very low. Major LAST events have decreased markedly since the early 1980s, likely related to increased awareness and routine incorporation of preventive measures into clinical practice [
         <a href="#rid3">
          3,4
         </a>
         ]. (See
         <a class="local">
          'Prevention of LAST'
         </a>
         below.)
        </p>
        <p>
         Data regarding the incidence of LAST come from registry studies and retrospective reviews of large numbers of regional anesthetics, based on very small numbers of events. Major LAST events are reported in 0.04 to 1.8/1000 peripheral nerve blocks. Examples of relevant studies include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one administrative database study, data was reviewed for 238,437 patients who received a peripheral nerve block for total joint arthroplasty between 2006 and 2014 [
         <a href="#rid5">
          5
         </a>
         ]. The overall incidence of LAST (defined as occurrence of cardiac arrest, seizure, and/or administration of lipid emulsion on the day of surgery) was 1.8 per 1000. The incidence of the composite outcomes declined over time (from 8.2 per 1000 in 2006 to 2.5 per 1000 in 2014), whereas the administration of lipid emulsion increased from 0.2 to 2.6 per 1000 over the same time period.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another review, data from the National Inpatient Sample in the United States was used to identify 710,327 patients who underwent total joint arthroplasty with an adjunctive peripheral nerve block between 1998 and 2013 [
         <a href="#rid6">
          6
         </a>
         ]. The incidence of LAST (identified by billing codes) was 1.04 per 1000, with major complications (ie, seizure or cardiac complications) in 21 percent of patients with LAST. The odds of LAST decreased by 10 percent per year over the study period.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective single institution analysis of approximately 80,600 peripheral nerve blocks from 2009 to 2014 reported three cases of seizures caused by LAST (0.04 per 1000) and no cases of cardiac arrest [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A review of data from the multicenter Australian and New Zealand Registry of Regional Anesthesia (AURORA) included data from approximately 25,300 peripheral nerve blocks performed from 2008 to 2012 [
         <a href="#rid8">
          8
         </a>
         ]. The overall incidence of minor and major LAST events was 0.87 per 1000 blocks. Major LAST events occurred in eight patients (0.31 per 1000), including seven cases of major central nervous system events (ie, seizure or unconsciousness) and one case of cardiac arrest. Ultrasound guidance (USG) was associated with reduced risk of LAST (0R 0.36 for minor and major LAST events).
        </p>
        <p>
        </p>
        <p>
         Other reviews have reported similarly low incidences of major LAST events [
         <a href="#rid9">
          9-13
         </a>
         ]. The incidence of major LAST may be higher with peripheral nerve block than with epidural block [
         <a href="#rid9">
          9
         </a>
         ], but this conclusion is based on very small numbers of events. Minor LAST events (eg, tinnitus, perioral numbness, metallic taste) probably occur much more frequently than major events, and go unreported.
        </p>
        <p class="headingAnchor" id="H2872791588">
         <span class="h1">
          PHARMACOLOGY AND PATHOPHARMACOLOGY OF LAST
         </span>
         <span class="headingEndMark">
          —
         </span>
         All local anesthetics have a hydrophobic aromatic ring and a hydrophilic amide group. The intermediary chain may contain either an ester or amide link, and dictates metabolism via plasma cholinesterases or hepatic oxidation, respectively. Local anesthetics are mostly achiral with few exceptions:
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         exists as a racemic mixture, while levobupivacaine and
         <a class="drug drug_general" data-topicid="9873" href="/z/d/drug information/9873.html" rel="external">
          ropivacaine
         </a>
         are pure enantiomers [
         <a href="#rid14">
          14
         </a>
         ]. The chirality of these compounds account for some of their subtle differences in clinical effects [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         The physiochemical properties of local anesthetics are responsible for individual pharmacokinetic differences among the clinically used agents [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <strong>
          pKa
         </strong>
         and its relationship to the surrounding pH influence the onset of effect due to the proportion of charged ionized drug to its uncharged un-ionized form [
         <a href="#rid15">
          15
         </a>
         ]. Lower pKa indicates that a greater proportion exists in the uncharged state, so more drug is available to transfer across the lipophilic cellular membrane to the effector site. (See
         <a class="medical medical_review" href="/z/d/html/6324.html" rel="external">
          "Subcutaneous infiltration of local anesthetics", section on 'Anatomy and physiology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similarly,
         <strong>
          lipophilicity
         </strong>
         correlates to potency, because a higher lipophilicity confers better ability to penetrate the lipid bilayer to the target [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Protein binding
         </strong>
         of the drug primarily to alpha-1-acidic glycoprotein, and to a lesser extent albumin, and tissue proteins relates to effect duration, serving as a reservoir for local anesthetic. A high affinity for protein binding decreases the effective circulating levels of free local anesthetic [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         All local anesthetics exert their effect primarily by blocking voltage-gated sodium channels (VGSC) at the alpha-subunit inside the channel, which prevents sodium influx, subsequent depolarization, and action potential generation [
         <a href="#rid16">
          16
         </a>
         ]. This conduction block impedes pain transmission from neuronal cells to the cerebral cortex, thereby producing analgesia and anesthesia. Toxicity occurs when LAs affect cardiac sodium channels [
         <a href="#rid17">
          17,18
         </a>
         ] or thalamocortical neurons in the brain [
         <a href="#rid19">
          19
         </a>
         ]. LAs have other, wide ranging effects, including blockade of potassium and calcium channels, interaction with cholinergic or N-methyl-D-aspartate (NMDA) receptors, and interference with cellular metabolic processes (eg, oxidative phosphorylation, free fatty acid utilization, cyclic adenosine monophosphate production). Such effects may explain some aspects of cardiovascular toxicity, and may relate to the mechanism for reversal of LAST with intravenous lipid emulsion (ILE). (See
         <a class="local">
          'Mechanism of action'
         </a>
         below and
         <a class="local">
          'Clinical presentation of toxicity'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3036059017">
         <span class="h2">
          Differences in toxicity among local anesthetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         <strong>
          All local anesthetics (LAs) may cause LAST
         </strong>
         with toxic plasma levels. However, cardiac toxicity and the relationship between central nervous system (CNS) and cardiac toxicity vary among LAs. Cardiac toxicity parallels the anesthetic potency for neural blockade [
         <a href="#rid20">
          20
         </a>
         ]; the more potent local anesthetics, including etidocaine and
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         , are more cardiotoxic than
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         .
        </p>
        <p class="headingAnchor" id="H2691863955">
         <span class="h3">
          Amide local anesthetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9873" href="/z/d/drug information/9873.html" rel="external">
          Ropivacaine
         </a>
         and levobupivacaine, which are prepared in almost pure S isomer form, are slightly less cardiotoxic [
         <a href="#rid21">
          21,22
         </a>
         ] and produce fewer CNS symptoms [
         <a href="#rid23">
          23
         </a>
         ] than
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         . The use of ropivacaine and levobupivacaine may help reduce cardiotoxicity, but does not eliminate the potential for LAST, especially at higher doses.
        </p>
        <p>
         LAs can be assigned a cardiovascular collapse (CC) to CNS ratio (CC:CNS), which is the ratio of the drug dose required to cause cardiac collapse to the drug dose required to produce seizures. LAs with higher CC:CNS theoretically have a greater margin of safety, as early CNS symptoms may allow intervention to prevent subsequent cardiac arrest. Based on animal models,
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         has the lowest CC:CNS ratio of the commonly used LAs, followed in increasing order by levobupivacaine,
         <a class="drug drug_general" data-topicid="9873" href="/z/d/drug information/9873.html" rel="external">
          ropivacaine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         LAs may have specific cardiac effects;
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         and
         <a class="drug drug_general" data-topicid="9610" href="/z/d/drug information/9610.html" rel="external">
          mepivacaine
         </a>
         primarily affect contractility, while
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         and
         <a class="drug drug_general" data-topicid="9873" href="/z/d/drug information/9873.html" rel="external">
          ropivacaine
         </a>
         tend to be more arrhythmogenic [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2298399361">
         <span class="h3">
          Ester local anesthetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9245" href="/z/d/drug information/9245.html" rel="external">
          Chloroprocaine
         </a>
         is a short acting ester LA that is metabolized by plasma cholinesterases, and may be used for epidural anesthesia and peripheral nerve blocks. Its very short plasma half-life may confer a degree of safety if inadvertent intravascular injection or systemic absorption occurs. The few LAST events that have been reported with chloroprocaine have been very brief. In single case reports, a 30 second seizure after paravertebral block [
         <a href="#rid26">
          26
         </a>
         ] and 40 second cardiac dysrhythmia after inadvertent intravascular injection during epidural block [
         <a href="#rid27">
          27
         </a>
         ] have been reported with chloroprocaine in infants. Minor LAST events lasting 3 to 11 minutes have also been reported after intravenous (IV) regional anesthesia using chloroprocaine [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         Plasma half-life of
         <a class="drug drug_general" data-topicid="9245" href="/z/d/drug information/9245.html" rel="external">
          chloroprocaine
         </a>
         may be prolonged in patients with pseudocholinesterase deficiency [
         <a href="#rid29">
          29
         </a>
         ] and in patients who take anticholinesterase medication (eg,
         <a class="drug drug_general" data-topicid="9838" href="/z/d/drug information/9838.html" rel="external">
          pyridostigmine
         </a>
         for myasthenia gravis) [
         <a href="#rid30">
          30
         </a>
         ], and presumably such patients are at risk for more prolonged LAST events. Clinicians should consider using a lower dose or an alternative local anesthetic, and should maintain a high level of clinical suspicion for toxicity when administering chloroprocaine in such patients. (See
         <a class="medical medical_review" href="/z/d/html/14929.html" rel="external">
          "Clinical use of local anesthetics in anesthesia", section on 'Metabolism of local anesthetics'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94256.html" rel="external">
          "Anesthesia for the patient with myasthenia gravis", section on 'Choice of anesthetic technique'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2588866267">
         <span class="h1">
          ROUTES OF LOCAL ANESTHETIC ADMINISTRATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         LAST may occur after any route of administration of local anesthetic (LA).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Regional anesthesia
         </strong>
         – The majority of reported cases of LAST have occurred after inadvertent intravenous (IV) injection of LA. However, systemic absorption from LA administration sites can also cause toxic blood levels, and may cause a delayed, gradual onset of symptoms and signs. Continuous LA infusion for regional analgesia can cause LAST by intravascular migration of the catheter or systemic absorption, and onset may occur hours or days after initial catheter placement. Rarely, LAST can occur after inadvertent low dose intraarterial injection during nerve block in the neck (eg, during interscalene block, cervical plexus block, or stellate ganglion block). In this setting, seizure usually occurs without cardiovascular effects, and usually resolves quickly [
         <a href="#rid31">
          31-34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical application
         </strong>
         –
         <strong>
         </strong>
         LAST can also occur after topical administration of LAs, especially when the drug is applied to mucosal membranes in repeated or high doses.
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          Lidocaine
         </a>
         used for topical oropharyngeal anesthesia is absorbed through mucous membranes, and from the gastrointestinal tract when swallowed. There are multiple case reports of seizures and cardiac arrest with high doses of oral viscous lidocaine, in adults [
         <a href="#rid35">
          35,36
         </a>
         ] and children [
         <a href="#rid37">
          37
         </a>
         ] (see
         <a class="local">
          'Patient risk factors'
         </a>
         below). LAST has been reported in children after inappropriate ingestion of other local anesthetic-containing preparations, such as topical analgesics that contain
         <a class="drug drug_general" data-topicid="8894" href="/z/d/drug information/8894.html" rel="external">
          dibucaine
         </a>
         [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         High blood levels of
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         have been measured after topical administration for bronchoscopy [
         <a href="#rid39">
          39,40
         </a>
         ], and cases of cardiac arrest have been reported [
         <a href="#rid41">
          41-43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Topical application of LAs to the skin can also result in high blood levels and toxicity. LAST has been reported after the use of EMLA cream [
         <a href="#rid44">
          44
         </a>
         ] and topical
         <a class="drug drug_general" data-topicid="10278" href="/z/d/drug information/10278.html" rel="external">
          tetracaine
         </a>
         in children [
         <a href="#rid45">
          45
         </a>
         ].
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          Lidocaine
         </a>
         applied to the face may result in high and variable blood levels, especially when used with an occlusive dressing [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3971070218">
         <span class="h1">
          RISK FACTORS FOR LAST
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk factors for LAST include patient factors that increase the free plasma drug concentration, or increase sensitivity to local anesthetics (LAs). Systemic absorption is increased at highly vascular block sites, independent of the drug or dose injected. In addition to total dose per body weight, these patient and procedural factors may significantly affect plasma levels in adults and therefore, contribute to increased risk for toxicity [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2097977506">
         <span class="h2">
          Patient risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Free LA in plasma may be increased by a low alpha 1 acid glycoprotein (AAG) level. In addition, patients with hyperdynamic circulation (eg, pregnancy, uremia) can rapidly absorb LA from injection sites, and plasma levels can rise quickly. Plasma LA levels after repeat dosing or infusion can be increased by impaired hepatic clearance.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extremes of
         </strong>
         <strong>
          age
         </strong>
         – Infants under the age of approximately four months have low levels of AAG, and may be at increased risk of LAST [
         <a href="#rid49">
          49,50
         </a>
         ]. They may also have immature hepatic clearance, and doses for repeat or continuous administration should be reduced by 15 percent from published standard doses for other ages [
         <a href="#rid51">
          51,52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Infants and young children may be at increased risk for LAST because of their small size, particularly with topical administration. As an example, it is easy to administer too large a dose of LA in what seems to be a small amount of LA gel. The US Food and Drug Administration (FDA) has issued a warning about the risks of severe LAST or death with the use of viscous
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         2% in young children.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In older adult patients, clearance of local anesthetics may be reduced due to deterioration of hepatic function and perfusion [
         <a href="#rid53">
          53
         </a>
         ]. Thus they may be at increased risk for LAST with repeat dosing or continuous infusion of LAs [
         <a href="#rid54">
          54
         </a>
         ]. In addition, nerves are more sensitive to LAs in older adults, and lower doses of LA are necessary for adequate block than in younger patients [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          End organ dysfunction
         </strong>
         – Generally, end organ dysfunction does not necessarily require dose adjustment, unless it is in its advanced stages.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cardiac disease
         </strong>
         – Many cases of LAST have occurred in patients with underlying ischemic or other cardiac disease [
         <a href="#rid31">
          31
         </a>
         ], but it is not clear that cardiac disease actually predisposes to LAST. Heart failure severe enough to affect hepatic and renal perfusion can reduce LA clearance, and increase the risk of LAST with repeat or continuous dosing [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Patients with ischemic heart disease or heart failure may be more difficult to resuscitate if cardiac toxicity does occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Renal insufficiency
         </strong>
         – Renal dysfunction does not increase risk for toxicity, unless metabolic acidosis ensues. The hyperdynamic circulation of uremic patients causes a rapid rise in LA plasma levels after large volume nerve block, but their high levels of AAG reduce the level of free drug [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hepatic disease
         </strong>
         – Hepatic dysfunction itself does not increase the risk of toxicity with single injection nerve blocks, unless liver disease is end stage, or associated with other comorbidities. Reduced LA clearance is offset by a larger volume of distribution for the initial injection and alpha-1-acid glycoprotein synthesis is usually preserved despite severe disease [
         <a href="#rid46">
          46,58
         </a>
         ]. However, severe liver disease increases the risk of LAST with continuous infusion or repeat block, and doses of LA should be reduced.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy
         </strong>
         – Pregnant patients, especially at term, are at increased risk for LAST, for several reasons:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hormonal changes may increase sensitivity of neural tissue to block [
         <a href="#rid59">
          59
         </a>
         ], and to cardiotoxicity [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduced levels of AAG and albumin may increase the free fraction of some LAs in pregnant patients [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The increased cardiac output of pregnancy may cause rapid absorption of LA after injection. Epidural venous engorgement may also increase absorption of LA during epidural anesthesia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lower pseudocholinesterase activity during pregnancy may reduce
         <a class="drug drug_general" data-topicid="9245" href="/z/d/drug information/9245.html" rel="external">
          chloroprocaine
         </a>
         metabolism and theoretically increase the duration of a LAST event if it occurs. (See
         <a class="local">
          'Ester local anesthetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The FDA issued a warning for the use of
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         , which states that bupivacaine 0.75% is not recommended for obstetrical anesthesia. The warning is based on reported cases of cardiac arrest with difficult resuscitation or death in obstetric patients who received bupivacaine for epidural anesthesia. Most of these cases involved administration of 0.75% bupivacaine, but LAST may occur with any concentration of LA.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Others
         </strong>
         – Metabolic disturbances such as acidosis, hypoxia, hypercarbia may increase the risk of toxicity [
         <a href="#rid62">
          62
         </a>
         ]. Carnitine deficiency also increases risk for cardiotoxicity, particularly with
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         [
         <a href="#rid63">
          63-65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2688469280">
         <span class="h2">
          Block site
         </span>
         <span class="headingEndMark">
          —
         </span>
         Injection of LA in highly vascular sites can increase the risk of direct intravascular injection and systemic absorption of LA. Regional anesthesia procedures that target particularly vascular sites include (in order of decreasing risk) intercostal blocks&gt; caudal and epidural anesthesia&gt; interfascial plane blocks of the abdominal wall&gt; psoas compartment blocks&gt; sciatic blocks&gt; and cervical and brachial plexus blocks [
         <a href="#rid66">
          66,67
         </a>
         ].
        </p>
        <p>
         Blocks that require large volumes and doses of local anesthetic may increase the risk of systemic absorption [
         <a href="#rid68">
          68
         </a>
         ]. As an example, interfascial plane blocks (eg, transversus abdominis plane [TAP] block) are often performed bilaterally, and involve injection of a total of ≥20 mL of LA per side to ensure adequate spread. Potentially neurotoxic plasma concentrations of LA have been reported in patients who received TAP blocks prior to laparotomy [
         <a href="#rid69">
          69,70
         </a>
         ], and neurotoxicity, including seizures, has been reported with TAP blocks in patients who are at increased risk of LAST (eg, renal or hepatic disease) [
         <a href="#rid71">
          71,72
         </a>
         ], and in parturients who received TAP block for pain relief after cesarean delivery [
         <a href="#rid73">
          73,74
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/122399.html" rel="external">
          "Transversus abdominis plane (TAP) blocks procedure guide", section on 'Complications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2090265223">
         <span class="h1">
          PREPARATION AND MONITORING FOR LAST
         </span>
         <span class="headingEndMark">
          —
         </span>
         Emergency resuscitation equipment should be available whenever local anesthetic is injected, to allow management of LAST and other complications of local anesthetic (LA) administration (eg, vagal response). Prior to performance of regional anesthesia (ie, peripheral nerve block, neuraxial block) or airway topicalization, intravenous (IV) access should be established, and monitors should be applied, including continuous pulse oximetry and electrocardiogram, and blood pressure monitoring.
        </p>
        <p>
         We follow the American Society of Regional Anesthesia and Pain Medicine (ASRA) safety checklist prior to performance of regional nerve blocks  (
         <a class="graphic graphic_table graphicRef113039" href="/z/d/graphic/113039.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid75">
          75
         </a>
         ]. The ASRA checklist incorporates features of the World Health Organization preanesthesia safety checklist  (
         <a class="graphic graphic_table graphicRef52392" href="/z/d/graphic/52392.html" rel="external">
          table 2
         </a>
         ), and includes a check for availability of resuscitation equipment, including vasoactive drugs and lipid emulsion.
        </p>
        <p>
         We administer supplemental oxygen to patients during performance of peripheral nerve blocks. We continue physiologic monitoring for at least 30 minutes after local anesthetic administration, to detect signs of delayed presentation of LAST.
        </p>
        <p class="headingAnchor" id="H1715459346">
         <span class="h1">
          PREVENTION OF LAST
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of techniques are used to reduce the risk of LAST, including utilizing the lowest effective dose, safe injection techniques, the use of ultrasound, and avoidance of heavy sedation.
        </p>
        <p class="headingAnchor" id="H2907251082">
         <span class="h2">
          Local anesthetic dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         The total dose of local anesthetic administered should be the lowest dose that is required for the desired extent and duration of block. Maximum allowable doses that appear in various publications are rough guidelines that are not evidence based, and don’t take into account the site or technique of local anesthetic (LA) administration, or patient factors that increase the risk of toxicity. Systemic toxicity may occur with doses within the recommended ranges, while doses in excess of the recommended maximums have been administered without toxicity [
         <a href="#rid23">
          23,76
         </a>
         ]. Nonetheless, published maximum recommended doses can be used as a starting point for deciding on a dose  (
         <a class="graphic graphic_table graphicRef93203" href="/z/d/graphic/93203.html" rel="external">
          table 3
         </a>
         ). The following general considerations should be followed (see
         <a class="local">
          'Patient risk factors'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maximum dose of local anesthetic should be based on lean, rather than actual body weight (
         <a class="calc calc_professional" href="/z/d/html/13408.html" rel="external">
          calculator 1
         </a>
         and
         <a class="calc calc_professional" href="/z/d/html/13407.html" rel="external">
          calculator 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dose of LA should be reduced for patients who are at risk for rapid uptake of LA from injection site (eg, pregnancy, uremia).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dose of LA should be reduced for patients with low levels of alpha 1 acid glycoprotein (eg, neonates, pregnant patients), who are at risk for high concentrations of free LA after injection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dose of LA should be reduced for patients who have increased neural sensitivity to LA (eg, older adults, pregnant patients).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dose of local anesthetic for continuous or repeat administration should be reduced for patients at risk for reduced clearance of LA (eg, renal, hepatic, or cardiac disease).
        </p>
        <p>
        </p>
        <p>
         Addition of
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         to LA solutions can slow the rate of absorption and reduce peak plasma levels [
         <a href="#rid77">
          77
         </a>
         ], and may act as a marker for intravascular injection. Epinephrine reduces the absorption of LA by 20 to 50 percent, depending on the site of injection and the LA [
         <a href="#rid47">
          47,77-79
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4287060227">
         <span class="h2">
          Safe injection techniques
         </span>
         <span class="headingEndMark">
          —
         </span>
         We use the following injection techniques for regional anesthesia, to reduce the risk of intravascular injection and for early detection of accidental intravascular injection:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Slow incremental injection
         </strong>
         – We administer LA incrementally, in 1 to 2 mL aliquots, with at least 30 to 45 seconds between injections. This delayed injection technique should allow for detection of accidental intravascular injection before toxic doses are given [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aspiration prior to injection
         </strong>
         – We aspirate gently prior to each incremental injection, and reposition the needle or catheter if we see blood return. Falsely negative aspiration is possible. As an example, in parturients, false negative aspiration with multi-orifice epidural catheters may be as high as 2 percent [
         <a href="#rid80">
          80-82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravascular marker
         </strong>
         – We add
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         (1:200,000 or 1:400,000) to most LA solutions (or used premixed epinephrine containing solutions) to act as a test dose for intravascular injection, in addition to the other effects of epinephrine. Intravascular injection of 15 mcg epinephrine usually results in an increase in heart rate of ≥10 beats per minute, and increase systolic blood pressure ≥15 mmHg within 20 to 40 seconds [
         <a href="#rid83">
          83
         </a>
         ], and is considered a positive test dose. Beta blockade, labor pain, advanced age, heavy sedation, and general anesthesia may confound the effects of epinephrine. (See
         <a class="medical medical_review" href="/z/d/html/101803.html" rel="external">
          "Neuraxial analgesia for labor and delivery (including instrumental delivery)", section on 'The epidural test dose in obstetrics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who are under general anesthesia, an increase in systolic blood pressure after an
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         containing test is a more reliable indicator of intravascular injection than an increase in heart rate, both during inhalation anesthesia, and total intravenous (IV) anesthesia [
         <a href="#rid84">
          84-86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H481885766">
         <span class="h2">
          Avoidance of heavy sedation or general anesthesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         We avoid heavy sedation during performance of regional anesthesia techniques, and perform such techniques under general anesthesia only when absolutely necessary. Patient feedback may help detect nerve injury (eg, by complaint of pain or paresthesia), progression of motor and sensory block, and early signs of LAST. Without appreciation of minor LAST symptoms (eg, tinnitus, circumoral numbness, dizziness), cardiovascular toxicity may occur as the first sign of LAST [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Regional anesthesia is routinely performed under general anesthesia for pediatric patients, and the risk of LAST appears to be very low when safe injection techniques are used. In a review of approximately 15,000 regional blocks reported to the Pediatric Regional Anesthesia Network, which is a multicenter collaborative network, there were no cases of LAST, though there were 13 cases of positive test dose, and 33 cases of vascular puncture [
         <a href="#rid87">
          87
         </a>
         ]. Ninety-five percent of blocks were placed during general anesthesia. Multicenter reviews of pediatric regional anesthesia in Europe have also reported very low rates of LAST [
         <a href="#rid88">
          88,89
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1070308687">
         <span class="h2">
          Ultrasound guidance
         </span>
         <span class="headingEndMark">
          —
         </span>
         We use ultrasound guidance (USG) for most peripheral nerve blocks, to improve the safety and efficacy of these techniques.
        </p>
        <p>
         USG may decrease the risk of LAST by several mechanisms:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced vascular puncture by visualization and avoidance of vascular structures, or by manual compression of vessels by the ultrasound transducer [
         <a href="#rid8">
          8,90
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of visualized spread of LA solution as confirmation of extravascular injection [
         <a href="#rid91">
          91
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced total LA dose, compared with landmark based or nerve stimulation based techniques [
         <a href="#rid92">
          92,93
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         The impact of USG on reducing LAST is debated. Large databases include very small numbers of LAST events, and randomized trials are too small to show an effect of block technique on LAST. As examples, a meta-analysis of 13 randomized controlled trials including approximately 950 patients that compared USG with peripheral nerve stimulation found that USG decreased the risk of vascular puncture during performance of peripheral nerve block (RR0.16), but studies were too small to draw conclusions about effects on LAST [
         <a href="#rid90">
          90
         </a>
         ]. A review of over 25,000 blocks in a multicenter registry database (AURORA) [
         <a href="#rid8">
          8
         </a>
         ], and a review of over 9000 blocks in a single institution database [
         <a href="#rid13">
          13
         </a>
         ] both found that USG reduced the incidence of LAST. However, the total number of major LAST events was small (14 in approximately 34,000 blocks between the two studies). Thus, definitive conclusions regarding a reduction in LAST with USG cannot be drawn. Regardless, major LAST events have been reported during USG, and vigilance should be maintained during any LA injection.
        </p>
        <p class="headingAnchor" id="H2851666358">
         <span class="h1">
          CLINICAL PRESENTATION OF TOXICITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical presentation of LAST is highly variable, and LAST should be suspected whenever physiologic changes occur after administration of local anesthetic (LA).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Onset
         </strong>
         – As classically described in the literature, LAST occurs soon after injection of LA, and progresses through central nervous system excitation, central nervous system (CNS) inhibition, cardiovascular excitation, and in extreme cases, cardiovascular inhibition and arrest. However, in a review of 93 reported LAST events that occurred during regional anesthesia over 30 years until 2009, only 60 percent of reported cases followed this classic presentation [
         <a href="#rid31">
          31
         </a>
         ]  (
         <a class="graphic graphic_figure graphicRef113648" href="/z/d/graphic/113648.html" rel="external">
          figure 1
         </a>
         ). In the remaining cases, onset was delayed or involved only cardiovascular (CV) effects, without CNS toxicity. In a subsequent review of 67 cases of LAST reported between 2010 and 2014, the distribution of signs and symptoms was similar to the previously reported cases, but a much greater proportion had an onset &gt;10 minutes after injection (42 versus 13 percent), and 22 percent occurred &gt;30 minutes after injection  (
         <a class="graphic graphic_figure graphicRef115426" href="/z/d/graphic/115426.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_figure graphicRef115425" href="/z/d/graphic/115425.html" rel="external">
          figure 3
         </a>
         and
         <a class="graphic graphic_figure graphicRef115423" href="/z/d/graphic/115423.html" rel="external">
          figure 4
         </a>
         and
         <a class="graphic graphic_figure graphicRef115424" href="/z/d/graphic/115424.html" rel="external">
          figure 5
         </a>
         ) [
         <a href="#rid34">
          34
         </a>
         ]. Similarly, in a review of 47 reported cases of LAST between 2014 and 2016, onset occurred after 10 minutes of LA injection in approximately 43 percent of cases, and approximately 23 percent occurred after 60 minutes [
         <a href="#rid94">
          94
         </a>
         ]. LAST occurred most commonly as a result of penile blocks in infants (23 percent of reports).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The presentation and speed of progression of symptoms depend on the route of systemic absorption, the local anesthetic plasma level, how quickly the concentration rises, and the characteristics of the specific LA. (See
         <a class="local">
          'Differences in toxicity among local anesthetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central nervous system effects
         </strong>
         – Local anesthetic blood levels in the brain initially block cortical inhibitory pathways, and may therefore cause excitatory signs and symptoms, including perioral numbness, metallic taste, mental status changes or anxiety, visual changes, muscle twitching, and ultimately, seizures. The more minor of these effects may occur with intravascular injection of a small dose of LA (eg, after an epidural test dose, or an incremental dose of LA during peripheral nerve block), or early after injection of larger doses. These symptoms and signs should alert the clinician to stop injection, and prepare for progression to more serious CNS and/or cardiovascular events  (
         <a class="graphic graphic_figure graphicRef115425" href="/z/d/graphic/115425.html" rel="external">
          figure 3
         </a>
         ). (See
         <a class="local">
          'Safe injection techniques'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Increasing blood levels then cause generalized CNS depression, which can result in somnolence, coma, and respiratory depression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular effects
         </strong>
         – CV signs and symptoms usually occur after or along with CNS symptoms during LAST, though they may occur alone. Initial sympathetic activation can cause tachycardia and hypertension. However, bradycardia and hypotension have often been described as the first changes in vital signs [
         <a href="#rid31">
          31
         </a>
         ]. CV toxicity can progress to ventricular arrhythmias and/or asystole  (
         <a class="graphic graphic_figure graphicRef115426" href="/z/d/graphic/115426.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The CV effects of systemic LA are complex and multifactorial, and are not completely understood. In laboratory studies, LA can block sodium, calcium [
         <a href="#rid95">
          95
         </a>
         ], and potassium channels [
         <a href="#rid96">
          96-99
         </a>
         ], and can cause conduction disturbances, impaired cardiac contractility, and loss of vascular tone.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1104607844">
         <span class="h1">
          MANAGEMENT OF LAST
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to the management of LAST is consistent with the guidelines and checklists published by the American Society of Regional Anesthesia and Pain Management (ASRA) [
         <a href="#rid100">
          100,101
         </a>
         ] and the Association of Anaesthetists of Great Britain and Ireland (AAGBI) [
         <a href="#rid102">
          102
         </a>
         ]  (
         <a class="graphic graphic_table graphicRef107887" href="/z/d/graphic/107887.html" rel="external">
          table 4
         </a>
         ). Key components of successful management include rapid response, maintenance of oxygenation and ventilation, seizure suppression, and cardiovascular support. Once LAST is suspected, the following steps should be followed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stop injection
         </strong>
         when any signs of intravascular injection occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Call for help
         </strong>
         –
         <strong>
         </strong>
         Call for qualified assistance, a LAST toxicity kit or lipid emulsion, and any available cognitive aid (eg, emergency manual), if progressive or severe signs or symptoms of LAST occur. Confirm or establish intravenous (IV) access.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Arrange for cardiopulmonary bypass
         </strong>
         –
         <strong>
         </strong>
         Alert the nearest facility with cardiopulmonary bypass (CPB) capability. Arranging for CPB takes time, and though it may not be necessary, CPB may be the last resort, and life-saving. CPB may be necessary while waiting for local anesthetic (LA) to diffuse from cardiac receptors, if advanced cardiac life support (ACLS) and IV lipid emulsion (ILE) fail.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Manage the airway
         </strong>
         –
         <strong>
         </strong>
         Administer 100 percent oxygen by face mask, and if necessary, control ventilation with a face mask, supraglottic airway, or endotracheal tube. The goal should be to prevent hypoxia and acidosis, as both potentiate LAST.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Suppress seizure
         </strong>
         –
         <strong>
         </strong>
         Suppress seizures immediately to reduce oxygen consumption, prevent hypoxia and hypercarbia, and prevent patient injury. Administration of a benzodiazepine is preferred (eg,
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         1 to 2 mg IV). Alternatively, small doses of
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         or thiopental may be used cautiously, as these drugs can cause hypotension and may exacerbate cardiovascular effects of LAST. If necessary, administer
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         to terminate tonic-clonic muscle activity and attenuate metabolic acidosis, recognizing that this will have no effect on central nervous system electrical activity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Manage arrhythmias and provide cardiovascular support
         </strong>
         –
         <strong>
         </strong>
         Management of arrhythmias and cardiac arrest as a result of LAST is different than other cardiac arrest scenarios, and may require prolonged effort. A goal is to maintain coronary perfusion and prevent cardiac tissue hypoxia. High quality chest compressions must be used during cardiac arrest, to perfuse the coronary arteries and to circulate lipid emulsion, which is usually administered simultaneously.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Advanced cardiac life support principles should be followed, with the following modifications:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Administer
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         as the first line antiarrhythmic (usual doses per ACLS), and avoid
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         and other sodium channel blockers (eg, other LAs, Class 1 antiarrhythmics [
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9378" href="/z/d/drug information/9378.html" rel="external">
          disopyramide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9648" href="/z/d/drug information/9648.html" rel="external">
          mexiletine
         </a>
         , tocainide], antiepileptic drugs).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduce the bolus dose of
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         to ≤1 mcg/kg IV to avoid arrhythmogenic effects. This recommendation is based on animal studies [
         <a href="#rid103">
          103,104
         </a>
         ], and the optimal dose of epinephrine is unknown.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Avoid
         <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">
          vasopressin
         </a>
         . In an animal model of
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         induced cardiac arrest, vasopressin was associated with poor hemodynamic and metabolic outcomes [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Avoid calcium channel blockers and beta blockers because of potential for exacerbating hypotension.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administer lipid rescue
         </strong>
         –
         <strong>
         </strong>
         Precise volumes and rate of administration of lipid emulsion are not crucial. Administer 20 percent lipid emulsion along with advanced cardiac life support or when neurotoxicity occurs, as follows (see
         <a class="local">
          'Lipid rescue'
         </a>
         below):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bolus lipid emulsion rapidly over two to three minutes and begin infusion based on patient ideal body weight as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          ≤70 kg
         </strong>
         – 1.5 mL/kg IV, followed by infusion at 0.25 mL/kg/minute IV
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          &gt;70 kg
         </strong>
         – 100 mL IV, followed by infusion of 200 to 250 mL IV over 15 to 20 minutes
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Repeat bolus once or twice and double infusion rate for persistent cardiovascular instability
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Continue infusion for at least 10 minutes after hemodynamic stability is achieved
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Maximum dose approximately 12 mL/kg
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          Propofol
         </a>
         is not a substitute for 20 percent lipid emulsion
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transfer patient to monitored setting
         </strong>
         –
         <strong>
         </strong>
         Upon successful stabilization, the patient should be safely and expeditiously transferred to a monitored setting that is staffed and equipped to continue recovery [
         <a href="#rid106">
          106
         </a>
         ]. Though it would be very unusual to occur, vigilance should still be maintained for possible recrudescence of LAST [
         <a href="#rid107">
          107
         </a>
         ]. The patient should be followed for any complications or side effects. And finally, cases of LAST or suspected LAST should be reported to the appropriate national registries for tracking [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3640819002">
         <span class="h1">
          LIPID RESCUE
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend administration of intravenous lipid emulsion (ILE) for patients with LAST who exhibit seizures or impending seizures, or signs of cardiovascular toxicity (ie, arrhythmias, severe hypotension, or cardiac arrest) along with ACLS. Though the optimal lipid preparation, dose of administration, and mechanism of action are unclear, LAST may be fatal, and adverse effects appear to be rare.
        </p>
        <p class="headingAnchor" id="H3730862635">
         <span class="h2">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Numerous case reports describe successful resuscitation of cardiac arrest related to LAST by intravenous (IV) infusion of lipid emulsion after patients failed to respond to standard advanced cardiac life support (ACLS) [
         <a href="#rid108">
          108-110
         </a>
         ]. Local anesthetics reported in these cases include
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9610" href="/z/d/drug information/9610.html" rel="external">
          mepivacaine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9873" href="/z/d/drug information/9873.html" rel="external">
          ropivacaine
         </a>
         , levobupivacaine, and
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         , used as sole agents or in combination. A systematic review of both human and animal studies involving IV lipid emulsion (ILE) therapy for LAST concluded that the published evidence was limited, and that ILE may be effective for reversal of cardiac or neurologic sequelae in some cases of LAST [
         <a href="#rid108">
          108
         </a>
         ]. There was no consistent evidence to support ILE therapy over vasopressors, or to determine whether one treatment should precede the other. However, this systematic review itself was severely limited by the lack of randomized controlled human trials, a heavy reliance on animal studies, and heterogeneity in study design, animal model utilized, and reported results.
        </p>
        <p class="headingAnchor" id="H3308416761">
         <span class="h2">
          Mechanism of action
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanism of action of lipid emulsion for treatment of LAST is unclear, and may be multifactorial, based on laboratory studies. Historically, lipid was thought to act as a "lipid sink," whereby lipid would bind the local anesthetic (LA) to remove it from target tissue. A somewhat different emerging theory is that lipid emulsion carries or "shuttles" the LA from the heart and brain to the organs that store and detoxify the drug [
         <a href="#rid111">
          111-115
         </a>
         ]. Lipid emulsion may also have direct cardiotonic effects involving sodium channels [
         <a href="#rid116">
          116
         </a>
         ], fatty acid processing [
         <a href="#rid117">
          117,118
         </a>
         ], and mitochondrial metabolism or permeability [
         <a href="#rid119">
          119
         </a>
         ], which would enhance the shuttling effect.
        </p>
        <p class="headingAnchor" id="H1195040195">
         <span class="h2">
          Timing of administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         The timing of lipid rescue therapy is controversial. We recommend administration of lipid emulsion immediately for patients with LAST who exhibit seizures or impending seizures, or signs of cardiovascular toxicity (ie, arrhythmias, severe hypotension, or cardiac arrest). We agree with the guidelines from the American Society for Regional Anesthesia and Pain Medicine (ASRA) [
         <a href="#rid100">
          100
         </a>
         ], the American Heart Association (AHA) [
         <a href="#rid120">
          120
         </a>
         ], and the Association of Anaesthetists of Great Britain and Ireland (AAGBI) [
         <a href="#rid102">
          102
         </a>
         ] that lipid emulsion should be administered concurrently as part of ACLS, if cardiac arrest is suspected to be a result of LAST.
        </p>
        <p class="headingAnchor" id="H1037320085">
         <span class="h2">
          Available formulations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal lipid preparation for treatment of LAST is debated [
         <a href="#rid121">
          121
         </a>
         ]. The formulation most commonly used has been 20 percent lipid emulsion (eg, Intralipid, Liposyn III 20%, or Nutrilipid) which is widely available in hospital formularies for nutritional support. Some formulations are also available in 10 and 30 percent concentrations, and animal studies suggest that at least some aspects of lipid rescue may be dose dependent [
         <a href="#rid122">
          122
         </a>
         ]. Further study is required before recommending concentrations of lipid emulsion other than 20 percent for treatment of LAST.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          Propofol
         </a>
         is prepared in 10 percent lipid emulsion. Propofol is never a suitable alternative to 20 percent lipid emulsion because of its cardiovascular depressant effects, particularly with the high volumes that would be required to treat LAST.
        </p>
        <p>
         The commercially available forms of 20 percent lipid emulsion contain soybean oil and egg yolk phospholipids, and should not be used in patients with true allergies to either of these food substances. The manufacturers state that lipid emulsion should be administered by IV infusion only, but intraosseous administration has been reported in a case in which IV access was lost [
         <a href="#rid123">
          123
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H318859207">
         <span class="h2">
          Dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal dose of lipid emulsion for LAST has not been determined. Multiple organizations have published guidance for lipid rescue therapy, including the ASRA [
         <a href="#rid100">
          100
         </a>
         ], the AAGBI [
         <a href="#rid102">
          102
         </a>
         ], and the American College of Medical Toxicology (ACMT) [
         <a href="#rid124">
          124
         </a>
         ]. ASRA recommends a dose of 100 mL over two to three minutes for patients &gt;70 kg, and 1.5 mL/kg for patients &lt;70 kg. The other organizations recommend an initial bolus of 1.5 mL/kg of 20 percent lipid emulsion for all patients. All recommend following the initial bolus with an infusion at 0.25 mL/kg/minute, and repeat bolus as necessary for persistent or recurrent cardiovascular instability. ASRA recommends using lean body weight.
        </p>
        <p class="bulletIndent1">
         These organizations have issued somewhat different recommendations regarding administration of lipid emulsion after the initial bolus and infusion as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ASRA [
         <a href="#rid100">
          100
         </a>
         ] – Continue infusion for at least 10 minutes after hemodynamic stability has been restored. Repeat bolus once or twice, and increase the infusion to 0.5 mL/kg/minute if hemodynamic instability persists or recurs. Maximum total dose 12 mL/kg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         AAGBI [
         <a href="#rid102">
          102
         </a>
         ] – Continue infusion until stable or maximum dose given, 12 mL/kg. Give up to two repeat bolus doses, five minutes apart, and double infusion to 0.5 mL/kg/minute at any time after five minutes, for persistent or recurrent cardiovascular instability.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ACMT [
         <a href="#rid124">
          124
         </a>
         ] – If there is an initial response, followed by re-emergence of hemodynamic instability, the infusion rate may be increased or the bolus repeated. Where possible lipid therapy should be discontinued after one hour or less. Longer treatment may be required.
        </p>
        <p>
        </p>
        <p>
         There is no published guidance on dosing of lipid emulsion for LAST associated with
         <a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">
          liposomal bupivacaine
         </a>
         , a sustained release formulation of
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         . The initial dose of lipid emulsion should presumably be the same as for other local anesthetics. The concern would be the possibility of prolonged LAST effects, as the peak plasma levels of bupivacaine can occur as long as 36 hours after injection of liposomal bupivacaine, with wide variability depending on injection site. Patients with LAST after liposomal bupivacaine may require prolonged infusion of lipid emulsion, and/or observation in a monitored setting. Liposomal bupivacaine is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/14929.html" rel="external">
          "Clinical use of local anesthetics in anesthesia", section on 'Liposomal bupivacaine'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4166411409">
         <span class="h2">
          Adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The safety of high volume lipid infusion for LAST is not precisely known. The most commonly reported adverse effect of lipid rescue has been the interference with laboratory testing, which may last for several hours after lipid administration [
         <a href="#rid125">
          125-127
         </a>
         ]. Centrifugation of blood samples substantially reduces interference [
         <a href="#rid128">
          128
         </a>
         ].
        </p>
        <p>
         Rare cases of pancreatitis and deep vein thrombosis have also occurred. Lipid emulsion may interfere with filters used for renal replacement therapy [
         <a href="#rid129">
          129,130
         </a>
         ], and importantly, may cause fat deposition and blood clots in cardiopulmonary bypass and extracorporeal membrane oxygenator circuits [
         <a href="#rid131">
          131
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3150540714">
         <span class="h2">
          Other therapeutic uses for lipid rescue
         </span>
         <span class="headingEndMark">
          —
         </span>
         Applications for lipid rescue include toxicity associated with a number of other lipophilic medications, including antiarrhythmics, anticonvulsants, antidepressants, antipsychotics, benzodiazepines and benzodiazepine-agonist, calcium channel blocker, cocaine, and diuretics [
         <a href="#rid132">
          132,133
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/330.html" rel="external">
          "Beta blocker poisoning", section on 'Lipid emulsion therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/331.html" rel="external">
          "Calcium channel blocker poisoning", section on 'Lipid emulsion therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3377339016">
         <span class="h1">
          CRISIS MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         LAST is a rare, potentially fatal event that requires a rapid multifactorial response. Similar to other critical incidents, the use of cognitive aids (eg, checklists) and simulation training are important components of optimal preparation and management. The uses of cognitive aids and simulation for perioperative emergencies are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94543.html" rel="external">
          "Cognitive aids for perioperative emergencies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15077.html" rel="external">
          "Patient safety in the operating room", section on 'Team and simulation training'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1642069470">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114014.html" rel="external">
          "Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/129826.html" rel="external">
          "Society guideline links: Local anesthetic systemic toxicity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3220533989">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rapid overview
         </strong>
         – The risk factors, clinical manifestations, and treatment of local anesthetic systemic toxicity (LAST) is shown in a table  (
         <a class="graphic graphic_table graphicRef107887" href="/z/d/graphic/107887.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Importance of LAST
         </strong>
         – LAST affects the central nervous system (CNS) and the cardiovascular system. While the reported incidence of major LAST events (eg, seizure, cardiac arrest) associated with regional anesthesia is very low (0.04 to 1.8 per 1000), such events may be fatal. (See
         <a class="local">
          'Incidence of LAST'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differences among local anesthetics
         </strong>
         – All local anesthetics have the potential to cause LAST. Cardiac toxicity and the relationship between cardiovascular (CV) toxicity and central nervous system (CNS) toxicity vary among local anesthetics.
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          Bupivacaine
         </a>
         is the most cardiotoxic of the commonly used LAs, followed in decreasing order by levobupivacaine,
         <a class="drug drug_general" data-topicid="9873" href="/z/d/drug information/9873.html" rel="external">
          ropivacaine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         . (See
         <a class="local">
          'Differences in toxicity among local anesthetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patient factors that increase the risk of LAST include extremes of age, renal, hepatic or cardiac disease, pregnancy, and metabolic disturbances. (See
         <a class="local">
          'Patient risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Procedural risk factors include highly vascular block sites and blocks that require large volumes of local anesthetics. (See
         <a class="local">
          'Block site'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – The risk of LAST during regional anesthesia may be reduced by the following (see
         <a class="local">
          'Prevention of LAST'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Limit the dose of local anesthetic to the lowest effective dose
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Add
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         1:200,000 to 1:400,000 to the local anesthetic solution as an intravascular marker
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Aspirate prior to each injection
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Inject small incremental doses (eg, 3 to 5 mL), assessing for signs of LAST between injections
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use ultrasound guidance for peripheral nerve blocks
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Avoid heavy sedation or general anesthesia during block procedures
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – The clinical presentation of LAST is highly variable  (
         <a class="graphic graphic_figure graphicRef113648" href="/z/d/graphic/113648.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Clinical presentation of toxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          CNS
         </strong>
         – LAST events often start with signs and symptoms of CNS excitation (eg, perioral numbness, metallic taste, mental status changes or anxiety, visual changes, muscle twitching, and ultimately, seizures), followed by CNS depression (eg, somnolence, coma, and respiratory depression).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          CV
         </strong>
         – CV signs and symptoms may occur along with or after CNS symptoms, and may include hypertension or hypotension, tachycardia or bradycardia, followed by ventricular arrhythmias and/or asystole.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – LAST should be recognized and treated rapidly, prioritizing prevention of hypoxia and acidosis, seizure suppression, and cardiovascular support, as outlined in the Rapid Overview  (
         <a class="graphic graphic_table graphicRef107887" href="/z/d/graphic/107887.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Management of LAST'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lipid rescue
         </strong>
         – We recommend administration of intravenous lipid emulsion (ILE) for patients with LAST who exhibit seizures or impending seizures, or signs of cardiovascular toxicity (ie, arrhythmias, severe hypotension, or cardiac arrest) along with ACLS (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ). Though the mechanism of action of lipid rescue and optional dose have yet to be determined, LAST may be fatal and adverse effects of lipid emulsion appear to be rare. Recommended doses of ILE are shown in the rapid overview  (
         <a class="graphic graphic_table graphicRef107887" href="/z/d/graphic/107887.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Lipid rescue'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Collins J. Awareness of local anaesthetic toxicity issues among hospital staff. Anaesthesia 2010; 65:960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sagir A, Goyal R. An assessment of the awareness of local anesthetic systemic toxicity among multi-specialty postgraduate residents. J Anesth 2015; 29:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulroy MF. Systemic toxicity and cardiotoxicity from local anesthetics: incidence and preventive measures. Reg Anesth Pain Med 2002; 27:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinberg G, Barron G. Local Anesthetic Systemic Toxicity (LAST): Not Gone, Hopefully Not Forgotten. Reg Anesth Pain Med 2016; 41:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mörwald EE, Zubizarreta N, Cozowicz C, et al. Incidence of Local Anesthetic Systemic Toxicity in Orthopedic Patients Receiving Peripheral Nerve Blocks. Reg Anesth Pain Med 2017; 42:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin DS, Matsumoto MM, Weinberg G, Roth S. Local Anesthetic Systemic Toxicity in Total Joint Arthroplasty: Incidence and Risk Factors in the United States From the National Inpatient Sample 1998-2013. Reg Anesth Pain Med 2018; 43:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu SS, Ortolan S, Sandoval MV, et al. Cardiac Arrest and Seizures Caused by Local Anesthetic Systemic Toxicity After Peripheral Nerve Blocks: Should We Still Fear the Reaper? Reg Anesth Pain Med 2016; 41:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrington MJ, Kluger R. Ultrasound guidance reduces the risk of local anesthetic systemic toxicity following peripheral nerve blockade. Reg Anesth Pain Med 2013; 38:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auroy Y, Benhamou D, Bargues L, et al. Major complications of regional anesthesia in France: The SOS Regional Anesthesia Hotline Service. Anesthesiology 2002; 97:1274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sites BD, Taenzer AH, Herrick MD, et al. Incidence of local anesthetic systemic toxicity and postoperative neurologic symptoms associated with 12,668 ultrasound-guided nerve blocks: an analysis from a prospective clinical registry. Reg Anesth Pain Med 2012; 37:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinonen JA, Litonius E, Pitkänen M, Rosenberg PH. Incidence of severe local anaesthetic toxicity and adoption of lipid rescue in Finnish anaesthesia departments in 2011-2013. Acta Anaesthesiol Scand 2015; 59:1032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ecoffey C, Oger E, Marchand-Maillet F, et al. Complications associated with 27 031 ultrasound-guided axillary brachial plexus blocks: a web-based survey of 36 French centres. Eur J Anaesthesiol 2014; 31:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orebaugh SL, Kentor ML, Williams BA. Adverse outcomes associated with nerve stimulator-guided and ultrasound-guided peripheral nerve blocks by supervised trainees: update of a single-site database. Reg Anesth Pain Med 2012; 37:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heavner JE. Local anesthetics. Curr Opin Anaesthesiol 2007; 20:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lirk P, Picardi S, Hollmann MW. Local anaesthetics: 10 essentials. Eur J Anaesthesiol 2014; 31:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Catterall WA. Voltage-gated sodium channels at 60: structure, function and pathophysiology. J Physiol 2012; 590:2577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Boghdadly K, Chin KJ. Local anesthetic systemic toxicity: Continuing Professional Development. Can J Anaesth 2016; 63:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scholz A. Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels. Br J Anaesth 2002; 89:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meuth SG, Budde T, Kanyshkova T, et al. Contribution of TWIK-related acid-sensitive K+ channel 1 (TASK1) and TASK3 channels to the control of activity modes in thalamocortical neurons. J Neurosci 2003; 23:6460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block A, Covino BG. Effect of local anesthetic agents on cardiac conduction and contractility. Regional Anesthesia 1981; 6:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bardsley H, Gristwood R, Baker H, et al. A comparison of the cardiovascular effects of levobupivacaine and rac-bupivacaine following intravenous administration to healthy volunteers. Br J Clin Pharmacol 1998; 46:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott DB, Lee A, Fagan D, et al. Acute toxicity of ropivacaine compared with that of bupivacaine. Anesth Analg 1989; 69:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knudsen K, Beckman Suurküla M, Blomberg S, et al. Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. Br J Anaesth 1997; 78:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groban L. Central nervous system and cardiac effects from long-acting amide local anesthetic toxicity in the intact animal model. Reg Anesth Pain Med 2003; 28:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfe JW, Butterworth JF. Local anesthetic systemic toxicity: update on mechanisms and treatment. Curr Opin Anaesthesiol 2011; 24:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernandez MA, Boretsky K. Chloroprocaine: local anesthetic systemic toxicity in a 9-month infant with paravertebral catheter. Paediatr Anaesth 2016; 26:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cladis FP, Litman RS. Transient cardiovascular toxicity with unintentional intravascular injection of 3% 2-chloroprocaine in a 2-month-old infant. Anesthesiology 2004; 100:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marsch SC, Sluga M, Studer W, et al. 0.5% versus 1.0% 2-chloroprocaine for intravenous regional anesthesia: a prospective, randomized, double-blind trial. Anesth Analg 2004; 98:1789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuhnert BR, Philipson EH, Pimental R, Kuhnert PM. A prolonged chloroprocaine epidural block in a postpartum patient with abnormal pseudocholinesterase. Anesthesiology 1982; 56:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raj PP, Ohlweiler D, Hitt BA, Denson DD. Kinetics of local anesthetic esters and the effects of adjuvant drugs on 2-chloroprocaine hydrolysis. Anesthesiology 1980; 53:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Gregorio G, Neal JM, Rosenquist RW, Weinberg GL. Clinical presentation of local anesthetic systemic toxicity: a review of published cases, 1979 to 2009. Reg Anesth Pain Med 2010; 35:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahli A, Coskun D, Akcali DT. Aetiology of convulsions due to stellate ganglion block: a review and report of two cases. Eur J Anaesthesiol 2002; 19:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujiwara S, Komasawa N, Kido H, Minami T. A rare case of accidental arterial local anesthetic injection under ultrasound-guided stellate ganglion block. J Clin Anesth 2016; 29:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vasques F, Behr AU, Weinberg G, et al. A Review of Local Anesthetic Systemic Toxicity Cases Since Publication of the American Society of Regional Anesthesia Recommendations: To Whom It May Concern. Reg Anesth Pain Med 2015; 40:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doumiri M, Moussaoui A, Maazouzi W. [Cardiac arrest after gargling and oral ingestion of 5% lidocaine]. Can J Anaesth 2008; 55:882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parish RC, Moore RT, Gotz VP. Seizures following oral lidocaine for esophageal anesthesia. Drug Intell Clin Pharm 1985; 19:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hess GP, Walson PD. Seizures secondary to oral viscous lidocaine. Ann Emerg Med 1988; 17:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dayan PS, Litovitz TL, Crouch BI, et al. Fatal accidental dibucaine poisoning in children. Ann Emerg Med 1996; 28:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ameer B, Burlingame MB, Harman EM. Rapid mucosal absorption of topical lidocaine during bronchoscopy in the presence of oral candidiasis. Chest 1989; 96:1438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labedzki L, Ochs HR, Abernethy DR, Greenblatt DJ. Potentially toxic serum lidocaine concentrations following spray anesthesia for bronchoscopy. Klin Wochenschr 1983; 61:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nath MP, Baruah R, Choudhury D, Chakrabarty A. Lignocaine toxicity after anterior nasal packing. Indian J Anaesth 2011; 55:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Day RO, Chalmers DR, Williams KM, Campbell TJ. The death of a healthy volunteer in a human research project: implications for Australian clinical research. Med J Aust 1998; 168:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horáček M, Vymazal T. Lidocaine not so innocent: Cardiotoxicity after topical anaesthesia for bronchoscopy. Indian J Anaesth 2012; 56:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rincon E, Baker RL, Iglesias AJ, Duarte AM. CNS toxicity after topical application of EMLA cream on a toddler with molluscum contagiosum. Pediatr Emerg Care 2000; 16:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maulidi H, McNair C, Seller N, et al. Arrhythmia associated with tetracaine in an extremely low birth weight premature infant. Pediatrics 2012; 130:e1704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oni G, Brown S, Burrus C, et al. Effect of 4% topical lidocaine applied to the face on the serum levels of lidocaine and its metabolite, monoethylglycinexylidide. Aesthet Surg J 2010; 30:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott DB, Jebson PJ, Braid DP, et al. Factors affecting plasma levels of lignocaine and prilocaine. Br J Anaesth 1972; 44:1040.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BRAID DP, SCOTT DB. THE SYSTEMIC ABSORPTION OF LOCAL ANALGESIC DRUGS. Br J Anaesth 1965; 37:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNamara PJ, Alcorn J. Protein binding predictions in infants. AAPS PharmSci 2002; 4:E4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anell-Olofsson M, Ahmadi S, Lönnqvist PA, et al. Plasma concentrations of alpha-1-acid glycoprotein in preterm and term newborns: influence of mode of delivery and implications for plasma protein binding of local anaesthetics. Br J Anaesth 2018; 121:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meunier JF, Goujard E, Dubousset AM, et al. Pharmacokinetics of bupivacaine after continuous epidural infusion in infants with and without biliary atresia. Anesthesiology 2001; 95:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsson BA, Lönnqvist PA, Olsson GL. Plasma concentrations of bupivacaine in neonates after continuous epidural infusion. Anesth Analg 1997; 84:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veering BT, Burm AG, van Kleef JW, et al. Epidural anesthesia with bupivacaine: effects of age on neural blockade and pharmacokinetics. Anesth Analg 1987; 66:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           bowdle, AT, Freund, et al. Age-dependent Lidocaine Pharmacokinetics During Lumbar Peridural Anesthesia with Lidocaine Hydrocarbonate or Lidocaine Hydrochloride. Regional Anesthesia 1986; 11:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paqueron X, Boccara G, Bendahou M, et al. Brachial plexus nerve block exhibits prolonged duration in the elderly. Anesthesiology 2002; 97:1245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomson PD, Melmon KL, Richardson JA, et al. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med 1973; 78:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pere P, Salonen M, Jokinen M, et al. Pharmacokinetics of ropivacaine in uremic and nonuremic patients after axillary brachial plexus block. Anesth Analg 2003; 96:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jokinen MJ, Neuvonen PJ, Lindgren L, et al. Pharmacokinetics of ropivacaine in patients with chronic end-stage liver disease. Anesthesiology 2007; 106:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butterworth JF 4th, Walker FO, Lysak SZ. Pregnancy increases median nerve susceptibility to lidocaine. Anesthesiology 1990; 72:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moller RA, Datta S, Fox J, et al. Effects of progesterone on the cardiac electrophysiologic action of bupivacaine and lidocaine. Anesthesiology 1992; 76:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsen LC, Tarshis J, Denson DD, et al. Measurements of maternal protein binding of bupivacaine throughout pregnancy. Anesth Analg 1999; 89:965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen MA, Thigpen JW, Shnider SM, et al. Bupivacaine-induced cardiotoxicity in hypoxic and acidotic sheep. Anesth Analg 1985; 64:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong GK, Joo DT, McDonnell C. Lipid resuscitation in a carnitine deficient child following intravascular migration of an epidural catheter. Anaesthesia 2010; 65:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinberg GL, Laurito CE, Geldner P, et al. Malignant ventricular dysrhythmias in a patient with isovaleric acidemia receiving general and local anesthesia for suction lipectomy. J Clin Anesth 1997; 9:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong GK, Crawford MW. Carnitine deficiency increases susceptibility to bupivacaine-induced cardiotoxicity in rats. Anesthesiology 2011; 114:1417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tucker GT, Moore DC, Bridenbaugh PO, et al. Systemic absorption of mepivacaine in commonly used regional block procedures. Anesthesiology 1972; 37:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tucker GT, Mather LE. Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet 1979; 4:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahiri J, Tuhoe J, Svirskis D, et al. Systematic review of the systemic concentrations of local anaesthetic after transversus abdominis plane block and rectus sheath block. Br J Anaesth 2017; 118:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffiths JD, Barron FA, Grant S, et al. Plasma ropivacaine concentrations after ultrasound-guided transversus abdominis plane block. Br J Anaesth 2010; 105:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kato N, Fujiwara Y, Harato M, et al. Serum concentration of lidocaine after transversus abdominis plane block. J Anesth 2009; 23:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakai T, Manabe W, Kamitani T, et al. [Ropivacaine-induced late-onset systemic toxicity after transversus abdominis plane block under general anesthesia: successful reversal with 20% lipid emulsion]. Masui 2010; 59:1502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landy C, Gagnon N, Boulland P, et al. Seizures associated with local anaesthetic intoxication. Br J Anaesth 2012; 109:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffiths JD, Le NV, Grant S, et al. Symptomatic local anaesthetic toxicity and plasma ropivacaine concentrations after transversus abdominis plane block for Caesarean section. Br J Anaesth 2013; 110:996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss E, Jolly C, Dumoulin JL, et al. Convulsions in 2 patients after bilateral ultrasound-guided transversus abdominis plane blocks for cesarean analgesia. Reg Anesth Pain Med 2014; 39:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulroy MF, Weller RS, Liguori GA. A checklist for performing regional nerve blocks. Reg Anesth Pain Med 2014; 39:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberg PH, Veering BT, Urmey WF. Maximum recommended doses of local anesthetics: a multifactorial concept. Reg Anesth Pain Med 2004; 29:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corvetto MA, Echevarría GC, De La Fuente N, et al. Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. Reg Anesth Pain Med 2012; 37:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karmakar MK, Ho AM, Law BK, et al. Arterial and venous pharmacokinetics of ropivacaine with and without epinephrine after thoracic paravertebral block. Anesthesiology 2005; 103:704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raj PP, Rosenblatt R, Miller J, et al. Dynamics of local-anesthetic compounds in regional anesthesia. Anesth Analg 1977; 56:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leighton BL, Topkis WG, Gross JB, et al. Multiport epidural catheters: does the air test work? Anesthesiology 2000; 92:1617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norris MC, Ferrenbach D, Dalman H, et al. Does epinephrine improve the diagnostic accuracy of aspiration during labor epidural analgesia? Anesth Analg 1999; 88:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norris MC, Fogel ST, Dalman H, et al. Labor epidural analgesia without an intravascular "test dose". Anesthesiology 1998; 88:1495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guay J. The epidural test dose: a review. Anesth Analg 2006; 102:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polaner DM, Zuk J, Luong K, Pan Z. Positive intravascular test dose criteria in children during total intravenous anesthesia with propofol and remifentanil are different than during inhaled anesthesia. Anesth Analg 2010; 110:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takahashi S, Tanaka M. Reduced efficacy of simulated epidural test doses in sevoflurane-anesthetized adults. Can J Anaesth 1999; 46:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka M, Takahashi S, Kondo T, Matsumiya N. Efficacy of simulated epidural test doses in adult patients anesthetized with isoflurane: a dose-response study. Anesth Analg 1995; 81:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polaner DM, Taenzer AH, Walker BJ, et al. Pediatric Regional Anesthesia Network (PRAN): a multi-institutional study of the use and incidence of complications of pediatric regional anesthesia. Anesth Analg 2012; 115:1353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ecoffey C, Lacroix F, Giaufré E, et al. Epidemiology and morbidity of regional anesthesia in children: a follow-up one-year prospective survey of the French-Language Society of Paediatric Anaesthesiologists (ADARPEF). Paediatr Anaesth 2010; 20:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Llewellyn N, Moriarty A. The national pediatric epidural audit. Paediatr Anaesth 2007; 17:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abrahams MS, Aziz MF, Fu RF, Horn JL. Ultrasound guidance compared with electrical neurostimulation for peripheral nerve block: a systematic review and meta-analysis of randomized controlled trials. Br J Anaesth 2009; 102:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neal JM. Ultrasound-guided regional anesthesia and patient safety: An evidence-based analysis. Reg Anesth Pain Med 2010; 35:S59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eren G, Altun E, Pektas Y, et al. To what extent can local anesthetics be reduced for infraclavicular block with ultrasound guidance? Anaesthesist 2014; 63:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donnell BD, Iohom G. Local anesthetic dose and volume used in ultrasound-guided peripheral nerve blockade. Int Anesthesiol Clin 2010; 48:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gitman M, Barrington MJ. Local Anesthetic Systemic Toxicity: A Review of Recent Case Reports and Registries. Reg Anesth Pain Med 2018; 43:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugiyama K, Muteki T. Local anesthetics depress the calcium current of rat sensory neurons in culture. Anesthesiology 1994; 80:1369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drachman D, Strichartz G. Potassium channel blockers potentiate impulse inhibition by local anesthetics. Anesthesiology 1991; 75:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olschewski A, Bräu ME, Olschewski H, et al. ATP-dependent potassium channel in rat cardiomyocytes is blocked by lidocaine. Possible impact on the antiarrhythmic action of lidocaine. Circulation 1996; 93:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheeler DM, Bradley EL, Woods WT Jr. The electrophysiologic actions of lidocaine and bupivacaine in the isolated, perfused canine heart. Anesthesiology 1988; 68:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valenzuela C, Delpón E, Tamkun MM, et al. Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. Biophys J 1995; 69:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neal JM, Barrington MJ, Fettiplace MR, et al. The Third American Society of Regional Anesthesia and Pain Medicine Practice Advisory on Local Anesthetic Systemic Toxicity: Executive Summary 2017. Reg Anesth Pain Med 2018; 43:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neal JM, Neal EJ, Weinberg GL. American Society of Regional Anesthesia and Pain Medicine Local Anesthetic Systemic Toxicity checklist: 2020 version. Reg Anesth Pain Med 2021; 46:81.
          </a>
         </li>
         <li class="breakAll">
          AAGBI Safety Guideline: Management of Severe Local Anesthetic Toxicity. https://www.aagbi.org/sites/default/files/la_toxicity_2010_0.pdf (Accessed on April 04, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo M, Yun X, Chen C, et al. Giving Priority to Lipid Administration Can Reduce Lung Injury Caused by Epinephrine in Bupivacaine-Induced Cardiac Depression. Reg Anesth Pain Med 2016; 41:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinberg GL, Di Gregorio G, Ripper R, et al. Resuscitation with lipid versus epinephrine in a rat model of bupivacaine overdose. Anesthesiology 2008; 108:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Gregorio G, Schwartz D, Ripper R, et al. Lipid emulsion is superior to vasopressin in a rodent model of resuscitation from toxin-induced cardiac arrest. Crit Care Med 2009; 37:993.
          </a>
         </li>
         <li class="breakAll">
          Cave G, Harrop-Griffiths W, Harvey M, et al. Management of Severe Local Anaesthetic Toxicity. AAGBI Safety Guideline 2010.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marwick PC, Levin AI, Coetzee AR. Recurrence of cardiotoxicity after lipid rescue from bupivacaine-induced cardiac arrest. Anesth Analg 2009; 108:1344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoegberg LC, Bania TC, Lavergne V, et al. Systematic review of the effect of intravenous lipid emulsion therapy for local anesthetic toxicity. Clin Toxicol (Phila) 2016; 54:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cave G, Harvey M, Graudins A. Intravenous lipid emulsion as antidote: a summary of published human experience. Emerg Med Australas 2011; 23:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cave G, Harvey M, Willers J, et al. LIPAEMIC report: results of clinical use of intravenous lipid emulsion in drug toxicity reported to an online lipid registry. J Med Toxicol 2014; 10:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litonius E, Tarkkila P, Neuvonen PJ, Rosenberg PH. Effect of intravenous lipid emulsion on bupivacaine plasma concentration in humans. Anaesthesia 2012; 67:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dureau P, Charbit B, Nicolas N, et al. Effect of Intralipid® on the Dose of Ropivacaine or Levobupivacaine Tolerated by Volunteers: A Clinical and Pharmacokinetic Study. Anesthesiology 2016; 125:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinonen JA, Litonius E, Salmi T, et al. Intravenous lipid emulsion given to volunteers does not affect symptoms of lidocaine brain toxicity. Basic Clin Pharmacol Toxicol 2015; 116:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi K, Xia Y, Wang Q, et al. The effect of lipid emulsion on pharmacokinetics and tissue distribution of bupivacaine in rats. Anesth Analg 2013; 116:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fettiplace MR, Lis K, Ripper R, et al. Multi-modal contributions to detoxification of acute pharmacotoxicity by a triglyceride micro-emulsion. J Control Release 2015; 198:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner M, Zausig YA, Ruf S, et al. Lipid rescue reverses the bupivacaine-induced block of the fast Na+ current (INa) in cardiomyocytes of the rat left ventricle. Anesthesiology 2014; 120:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Partownavid P, Umar S, Li J, et al. Fatty-acid oxidation and calcium homeostasis are involved in the rescue of bupivacaine-induced cardiotoxicity by lipid emulsion in rats. Crit Care Med 2012; 40:2431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Umar S, Li J, Hannabass K, et al. Free Fatty Acid Receptor G-protein-coupled Receptor 40 Mediates Lipid Emulsion-induced Cardioprotection. Anesthesiology 2018; 129:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahman S, Li J, Bopassa JC, et al. Phosphorylation of GSK-3β mediates intralipid-induced cardioprotection against ischemia/reperfusion injury. Anesthesiology 2011; 115:242.
          </a>
         </li>
         <li class="breakAll">
          https://eccguidelines.heart.org/wp-content/themes/eccstaging/dompdf-master/pdffiles/part-10-special-circumstances-of-resuscitation.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruan W, French D, Wong A, et al. A mixed (long- and medium-chain) triglyceride lipid emulsion extracts local anesthetic from human serum in vitro more effectively than a long-chain emulsion. Anesthesiology 2012; 116:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fettiplace MR, Ripper R, Lis K, et al. Rapid cardiotonic effects of lipid emulsion infusion*. Crit Care Med 2013; 41:e156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sampson CS, Bedy SM. Lipid emulsion therapy given intraosseously in massive verapamil overdose. Am J Emerg Med 2015; 33:1844.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American College of Medical Toxicology. ACMT Position Statement: Guidance for the Use of Intravenous Lipid Emulsion. J Med Toxicol 2017; 13:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine M, Skolnik AB, Ruha AM, et al. Complications following antidotal use of intravenous lipid emulsion therapy. J Med Toxicol 2014; 10:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grunbaum AM, Gilfix BM, Gosselin S, Blank DW. Analytical interferences resulting from intravenous lipid emulsion. Clin Toxicol (Phila) 2012; 50:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grunbaum AM, Gilfix BM, Hoffman RS, et al. Review of the effect of intravenous lipid emulsion on laboratory analyses. Clin Toxicol (Phila) 2016; 54:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz ES, Arroyo-Plasencia AM, Mullins ME. Other complications following lipid emulsion therapy : Re: Levine M, Skolnik AB, Ruha AM, et al. (2013) Complications following antidotal use of intravenous lipid emulsion therapy. J Med Toxicol Dec 13. [Epub ahead of print]. J Med Toxicol 2014; 10:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodríguez B, Wilhelm A, Kokko KE. Lipid emulsion use precluding renal replacement therapy. J Emerg Med 2014; 47:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeong J. Continuous renal replacement therapy circuit failure after antidote administration. Clin Toxicol (Phila) 2014; 52:1296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee HM, Archer JR, Dargan PI, Wood DM. What are the adverse effects associated with the combined use of intravenous lipid emulsion and extracorporeal membrane oxygenation in the poisoned patient? Clin Toxicol (Phila) 2015; 53:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muller SH, Diaz JH, Kaye AD. Intralipid Emulsion Rescue Therapy: Emerging Therapeutic Indications in Medical Practice. J La State Med Soc 2016; 168:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jakkala-Saibaba R, Morgan PG, Morton GL. Treatment of cocaine overdose with lipid emulsion. Anaesthesia 2011; 66:1168.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 90613 Version 27.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21198500" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Awareness of local anaesthetic toxicity issues among hospital staff.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25138822" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : An assessment of the awareness of local anesthetic systemic toxicity among multi-specialty postgraduate residents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12430104" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Systemic toxicity and cardiotoxicity from local anesthetics: incidence and preventive measures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26678759" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Local Anesthetic Systemic Toxicity (LAST): Not Gone, Hopefully Not Forgotten.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28079735" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Incidence of Local Anesthetic Systemic Toxicity in Orthopedic Patients Receiving Peripheral Nerve Blocks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29280923" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Local Anesthetic Systemic Toxicity in Total Joint Arthroplasty: Incidence and Risk Factors in the United States From the National Inpatient Sample 1998-2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26650424" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Cardiac Arrest and Seizures Caused by Local Anesthetic Systemic Toxicity After Peripheral Nerve Blocks: Should We Still Fear the Reaper?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23788067" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Ultrasound guidance reduces the risk of local anesthetic systemic toxicity following peripheral nerve blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12411815" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Major complications of regional anesthesia in France: The SOS Regional Anesthesia Hotline Service.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22705953" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Incidence of local anesthetic systemic toxicity and postoperative neurologic symptoms associated with 12,668 ultrasound-guided nerve blocks: an analysis from a prospective clinical registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25939497" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Incidence of severe local anaesthetic toxicity and adoption of lipid rescue in Finnish anaesthesia departments in 2011-2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24809480" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Complications associated with 27 031 ultrasound-guided axillary brachial plexus blocks: a web-based survey of 36 French centres.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22996199" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Adverse outcomes associated with nerve stimulator-guided and ultrasound-guided peripheral nerve blocks by supervised trainees: update of a single-site database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17620842" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Local anesthetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25192265" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Local anaesthetics: 10 essentials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22473783" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Voltage-gated sodium channels at 60: structure, function and pathophysiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26830640" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Local anesthetic systemic toxicity: Continuing Professional Development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12173241" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12878686" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Contribution of TWIK-related acid-sensitive K+ channel 1 (TASK1) and TASK3 channels to the control of activity modes in thalamocortical neurons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Effect of local anesthetic agents on cardiac conduction and contractility
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9764965" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A comparison of the cardiovascular effects of levobupivacaine and rac-bupivacaine following intravenous administration to healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2679230" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Acute toxicity of ropivacaine compared with that of bupivacaine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9175963" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12567336" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Central nervous system and cardiac effects from long-acting amide local anesthetic toxicity in the intact animal model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21841477" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Local anesthetic systemic toxicity: update on mechanisms and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27089835" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Chloroprocaine: local anesthetic systemic toxicity in a 9-month infant with paravertebral catheter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14695742" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Transient cardiovascular toxicity with unintentional intravascular injection of 3% 2-chloroprocaine in a 2-month-old infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15155349" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : 0.5% versus 1.0% 2-chloroprocaine for intravenous regional anesthesia: a prospective, randomized, double-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7081736" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A prolonged chloroprocaine epidural block in a postpartum patient with abnormal pseudocholinesterase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7425357" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Kinetics of local anesthetic esters and the effects of adjuvant drugs on 2-chloroprocaine hydrolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20301824" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Clinical presentation of local anesthetic systemic toxicity: a review of published cases, 1979 to 2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12095020" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Aetiology of convulsions due to stellate ganglion block: a review and report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26897437" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A rare case of accidental arterial local anesthetic injection under ultrasound-guided stellate ganglion block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26469367" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A Review of Local Anesthetic Systemic Toxicity Cases Since Publication of the American Society of Regional Anesthesia Recommendations: To Whom It May Concern.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19050099" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : [Cardiac arrest after gargling and oral ingestion of 5% lidocaine].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3979259" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Seizures following oral lidocaine for esophageal anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3382075" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Seizures secondary to oral viscous lidocaine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8839533" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Fatal accidental dibucaine poisoning in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2582861" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Rapid mucosal absorption of topical lidocaine during bronchoscopy in the presence of oral candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6865269" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Potentially toxic serum lidocaine concentrations following spray anesthesia for bronchoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22013274" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Lignocaine toxicity after anterior nasal packing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9612458" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The death of a healthy volunteer in a human research project: implications for Australian clinical research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22529438" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Lidocaine not so innocent: Cardiotoxicity after topical anaesthesia for bronchoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10966344" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : CNS toxicity after topical application of EMLA cream on a toddler with molluscum contagiosum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23129077" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Arrhythmia associated with tetracaine in an extremely low birth weight premature infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21131461" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Effect of 4% topical lidocaine applied to the face on the serum levels of lidocaine and its metabolite, monoethylglycinexylidide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4639822" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Factors affecting plasma levels of lignocaine and prilocaine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14328270" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : THE SYSTEMIC ABSORPTION OF LOCAL ANALGESIC DRUGS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12049488" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Protein binding predictions in infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30032881" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Plasma concentrations of alpha-1-acid glycoprotein in preterm and term newborns: influence of mode of delivery and implications for plasma protein binding of local anaesthetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11465589" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Pharmacokinetics of bupivacaine after continuous epidural infusion in infants with and without biliary atresia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9052290" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Plasma concentrations of bupivacaine in neonates after continuous epidural infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3605667" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Epidural anesthesia with bupivacaine: effects of age on neural blockade and pharmacokinetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Age-dependent Lidocaine Pharmacokinetics During Lumbar Peridural Anesthesia with Lidocaine Hydrocarbonate or Lidocaine Hydrochloride.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12411811" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Brachial plexus nerve block exhibits prolonged duration in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4694036" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12538213" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Pharmacokinetics of ropivacaine in uremic and nonuremic patients after axillary brachial plexus block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17197844" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Pharmacokinetics of ropivacaine in patients with chronic end-stage liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2350034" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Pregnancy increases median nerve susceptibility to lidocaine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1550285" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Effects of progesterone on the cardiac electrophysiologic action of bupivacaine and lidocaine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10512273" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Measurements of maternal protein binding of bupivacaine throughout pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4051206" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Bupivacaine-induced cardiotoxicity in hypoxic and acidotic sheep.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19849674" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Lipid resuscitation in a carnitine deficient child following intravascular migration of an epidural catheter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9438897" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Malignant ventricular dysrhythmias in a patient with isovaleric acidemia receiving general and local anesthesia for suction lipectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21537157" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Carnitine deficiency increases susceptibility to bupivacaine-induced cardiotoxicity in rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5051605" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Systemic absorption of mepivacaine in commonly used regional block procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/385208" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Clinical pharmacokinetics of local anaesthetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28403398" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Systematic review of the systemic concentrations of local anaesthetic after transversus abdominis plane block and rectus sheath block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20861094" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Plasma ropivacaine concentrations after ultrasound-guided transversus abdominis plane block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19444577" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Serum concentration of lidocaine after transversus abdominis plane block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21229691" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : [Ropivacaine-induced late-onset systemic toxicity after transversus abdominis plane block under general anesthesia: successful reversal with 20% lipid emulsion].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22879663" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Seizures associated with local anaesthetic intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23454825" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Symptomatic local anaesthetic toxicity and plasma ropivacaine concentrations after transversus abdominis plane block for Caesarean section.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24682078" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Convulsions in 2 patients after bilateral ultrasound-guided transversus abdominis plane blocks for cesarean analgesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24718017" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : A checklist for performing regional nerve blocks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15635516" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Maximum recommended doses of local anesthetics: a multifactorial concept.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23038415" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16192762" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Arterial and venous pharmacokinetics of ropivacaine with and without epinephrine after thoracic paravertebral block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/556897" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Dynamics of local-anesthetic compounds in regional anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10839910" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Multiport epidural catheters: does the air test work?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10320171" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Does epinephrine improve the diagnostic accuracy of aspiration during labor epidural analgesia?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9637642" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Labor epidural analgesia without an intravascular "test dose".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16492853" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The epidural test dose: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19933529" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Positive intravascular test dose criteria in children during total intravenous anesthesia with propofol and remifentanil are different than during inhaled anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10349922" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Reduced efficacy of simulated epidural test doses in sevoflurane-anesthetized adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7486089" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Efficacy of simulated epidural test doses in adult patients anesthetized with isoflurane: a dose-response study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22696610" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Pediatric Regional Anesthesia Network (PRAN): a multi-institutional study of the use and incidence of complications of pediatric regional anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21199114" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Epidemiology and morbidity of regional anesthesia in children: a follow-up one-year prospective survey of the French-Language Society of Paediatric Anaesthesiologists (ADARPEF).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17498013" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : The national pediatric epidural audit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19174373" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Ultrasound guidance compared with electrical neurostimulation for peripheral nerve block: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20216027" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Ultrasound-guided regional anesthesia and patient safety: An evidence-based analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25098777" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : To what extent can local anesthetics be reduced for infraclavicular block with ultrasound guidance?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20881526" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Local anesthetic dose and volume used in ultrasound-guided peripheral nerve blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29303925" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Local Anesthetic Systemic Toxicity: A Review of Recent Case Reports and Registries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8010481" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Local anesthetics depress the calcium current of rat sensory neurons in culture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1741497" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Potassium channel blockers potentiate impulse inhibition by local anesthetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8640992" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : ATP-dependent potassium channel in rat cardiomyocytes is blocked by lidocaine. Possible impact on the antiarrhythmic action of lidocaine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3341573" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : The electrophysiologic actions of lidocaine and bupivacaine in the isolated, perfused canine heart.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8527655" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29356773" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : The Third American Society of Regional Anesthesia and Pain Medicine Practice Advisory on Local Anesthetic Systemic Toxicity: Executive Summary 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33148630" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : American Society of Regional Anesthesia and Pain Medicine Local Anesthetic Systemic Toxicity checklist: 2020 version.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33148630" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : American Society of Regional Anesthesia and Pain Medicine Local Anesthetic Systemic Toxicity checklist: 2020 version.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27281728" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Giving Priority to Lipid Administration Can Reduce Lung Injury Caused by Epinephrine in Bupivacaine-Induced Cardiac Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18431127" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Resuscitation with lipid versus epinephrine in a rat model of bupivacaine overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19237909" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Lipid emulsion is superior to vasopressin in a rodent model of resuscitation from toxin-induced cardiac arrest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19237909" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Lipid emulsion is superior to vasopressin in a rodent model of resuscitation from toxin-induced cardiac arrest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19299810" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Recurrence of cardiotoxicity after lipid rescue from bupivacaine-induced cardiac arrest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26853119" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Systematic review of the effect of intravenous lipid emulsion therapy for local anesthetic toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21489160" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Intravenous lipid emulsion as antidote: a summary of published human experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24414252" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : LIPAEMIC report: results of clinical use of intravenous lipid emulsion in drug toxicity reported to an online lipid registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22352703" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Effect of intravenous lipid emulsion on bupivacaine plasma concentration in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27404223" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Effect of Intralipid®on the Dose of Ropivacaine or Levobupivacaine Tolerated by Volunteers: A Clinical and Pharmacokinetic Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25207682" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Intravenous lipid emulsion given to volunteers does not affect symptoms of lidocaine brain toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23460566" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : The effect of lipid emulsion on pharmacokinetics and tissue distribution of bupivacaine in rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25483426" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Multi-modal contributions to detoxification of acute pharmacotoxicity by a triglyceride micro-emulsion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23941864" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Lipid rescue reverses the bupivacaine-induced block of the fast Na+ current (INa) in cardiomyocytes of the rat left ventricle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22647409" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Fatty-acid oxidation and calcium homeostasis are involved in the rescue of bupivacaine-induced cardiotoxicity by lipid emulsion in rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29620570" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Free Fatty Acid Receptor G-protein-coupled Receptor 40 Mediates Lipid Emulsion-induced Cardioprotection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21691195" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Phosphorylation of GSK-3βmediates intralipid-induced cardioprotection against ischemia/reperfusion injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21691195" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Phosphorylation of GSK-3βmediates intralipid-induced cardioprotection against ischemia/reperfusion injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22273855" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : A mixed (long- and medium-chain) triglyceride lipid emulsion extracts local anesthetic from human serum in vitro more effectively than a long-chain emulsion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23531591" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Rapid cardiotonic effects of lipid emulsion infusion*.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26003744" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Lipid emulsion therapy given intraosseously in massive verapamil overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27121236" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : ACMT Position Statement: Guidance for the Use of Intravenous Lipid Emulsion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24338451" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Complications following antidotal use of intravenous lipid emulsion therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23075253" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Analytical interferences resulting from intravenous lipid emulsion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26623668" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Review of the effect of intravenous lipid emulsion on laboratory analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24639198" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Other complications following lipid emulsion therapy : Re: Levine M, Skolnik AB, Ruha AM, et al. (2013) Complications following antidotal use of intravenous lipid emulsion therapy. J Med Toxicol Dec 13. [Epub ahead of print].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25271183" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Lipid emulsion use precluding renal replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25410492" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Continuous renal replacement therapy circuit failure after antidote administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25634667" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : What are the adverse effects associated with the combined use of intravenous lipid emulsion and extracorporeal membrane oxygenation in the poisoned patient?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27389379" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Intralipid Emulsion Rescue Therapy: Emerging Therapeutic Indications in Medical Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22074030" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Treatment of cocaine overdose with lipid emulsion.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
